Test Discontinuation Memorandum

Effective December 21, 2015, Baylor Miraca Genetics Laboratories (BMGL) will discontinue the following tests:

  • Test code 6001 – Ashkenazic Genetic Disease Panel
  • Test code 6030 – Familial Dysautonomia Ashkenazic Mutation Panel
  • Test code 6033 – Gaucher Disease Ashkenazic Mutation Panel
  • Test code 6047 – Niemann-Pick Disease Type A Mutation Analysis
  • Test code 6066 – Tay-Sachs Disease Mutation Analysis
  • Test code 6070 – Canavan Disease Ashkenazic Mutation Panel
  • Test code 7600 – CFTR-Related Disorders Mutation Panel

The following tests may be considered as alternative ordering options:

  • If carrier screening for a person of Ashkenazic Jewish ancestry is desired, consider GeneAware Ashkenazi Jewish Panel (test code 60201 for females and 60206 for males). If carrier screening for a person of non-Ashkenazic Jewish ancestry is desired, consider one of our other GeneAware Panels (see our website www.BMGL.com for more information).
  • If symptomatic for Familial Dysautonomia, consider test code 29370, IKBKAP Gene Sequencing by Massively Parallel Sequencing.
  • If symptomatic for Gaucher Disease, consider test code 4554, Beta-Glucosidase Enzyme Analysis. No diagnostic molecular study replaces this code.
  • If symptomatic for Niemann-Pick Disease, type A, consider test code 4608 or 4607, Sphingomyelinase Enzyme Assay. No diagnostic molecular study replaces this code.
  • If symptomatic for Tay Sachs Disease, consider test code 6925, HEXA Sequence Analysis.
  • If symptomatic for Canavan Disease, consider test code 29285, ASPA Gene Sequencing by Massively Parallel Sequencing.
  • If symptomatic for CFTR related disorders, consider test code 6376 CFTR Comprehensive – Sequence & Deletion/Duplication Analysis.
Previous Post
Test Discontinuation Memorandum
Next Post
Baylor Genetics Announces Strategic Partnership With Diversigen
Menu